To assess the risk of gastrointestinal bleeding associated with the concomitant use of direct oral anticoagulants (DOACs) and COX-2–selective NSAIDs compared with nonselective NSAIDs among patients with nonvalvular atrial fibrillation (NVAF).
Key Findings:
NSAIDs increase the risk of gastrointestinal bleeding up to 4 times compared with nonuse.
COX-2 selective NSAIDs can reduce the risk of GI bleeding by up to 60% compared to nonselective NSAIDs.
Limited data exists on the effects of COX-2 selective NSAIDs in patients with NVAF using DOACs.
Interpretation:
Limitations:
The study may not capture all potential confounding factors influencing GI bleeding.
Data is reliant on the accuracy of medical records and coding within the databases.
Conclusion:
The study aims to assess the risk of gastrointestinal bleeding associated with NSAID use in NVAF patients on DOACs.
